Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation

Rhea-AI Summary

The settlement of patent disputes regarding Injectafer® (ferric carboxymaltose) has been reached by Vifor Pharma and American Regent, resolving litigation with Mylan Laboratories and Sandoz. Under the agreement, Mylan and Sandoz will be allowed to market generic versions in the U.S. starting July 1, 2026, pending FDA approval. Dr. Oliver P. Kronenberg stated the company can now focus on addressing iron deficiency anemia, a condition affecting over 1.7 million patients in the U.S.

Positive

• Settlement of patent litigation allows for future focus on iron deficiency treatments.
• Injectafer® has treated over 1.7 million patients in the U.S.
• Product has been studied in more than 40 clinical trials with over 8,800 patients.

Negative

• Generic competitors will enter the market in July 2026, which may affect market share.

• Abbreviated New Drug Application (ANDA) disputes regarding Injectafer^® (ferric carboxymaltose) have now been settled

ST. GALLEN, Switzerland & SHIRLEY, N.Y.--(BUSINESS WIRE)-- Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sankyo Group company, today announced that they have reached settlement agreements with Mylan Laboratories Ltd., and Sandoz, Inc., that resolve the patent litigation brought in response to Abbreviated New Drug Applications seeking approval by the U.S. Food and Drug Administration to market a generic version of Injectafer^®.

Under the terms of the settlements, Vifor Pharma and American Regent will grant Mylan Laboratories Ltd., and Sandoz, Inc., licenses to market generic ferric carboxymaltose products in the United States beginning 1 July 2026 (subject to U.S. FDA approval). Details of all settlements are confidential.

“We are pleased to have settled all outstanding patent litigations regarding Injectafer^®,” commented Dr. Oliver P. Kronenberg, Group General Counsel of Vifor Pharma. “With these agreements in place, we can continue to focus on addressing the significant remaining unmet medical need to diagnose and appropriately treat iron deficiency anemia to improve lives of U.S. patients, together with our partner American Regent.”

“Injectafer^® is an important treatment option for patients with iron deficiency anemia”, said Gretchen Fritz, Chief Legal Officer of American Regent. “American Regent is proud of the innovation and decades of hard work that made this treatment option possible and available to patients in the U.S. We are pleased to resolve the burdens of litigation, and excited for future results of our ongoing robust clinical program for Injectafer^®.”

In the US, more than 1.7 million patients have been treated for iron deficiency anemia. Injectafer^® has been studied in more than 40 clinical trials that included over 8,800 patients worldwide. Injectafer^® has been approved in 83 countries since initial European Union (EU) approval in 2007 and is the most extensively studied intravenous iron.

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.

About American Regent, Inc.
American Regent, Inc., a Daiichi Sankyo Group company, is a top-10 injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For nearly 20 years, we have been a leader in IV iron therapy. American Regent is committed to U.S.-based manufacturing. In 2018, more than 99% of units supplied were formulated, filled, and finished at our U.S.-based facilities, making us uniquely positioned to quickly mobilize to respond to shortages or changes in market needs. Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need. For more information, please visit www.americanregent.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211219005059/en/

Media Relations

Nathalie Ponnier

Global Head Corporate Communications

+41 79 957 96 73

media@viforpharma.com

Investor Relations

Laurent de Weck

Investor Relations & Treasury Senior Manager

+41 58 851 66 90

investors@viforpharma.com

Source: Vifor Pharma Group

FAQ

What does the recent press release about GNHAY state regarding Injectafer®?

The press release announces that patent litigation related to Injectafer® has been settled, allowing for the marketing of generic versions starting July 1, 2026.

When can generic versions of Injectafer® be marketed according to the press release?

Generic versions of Injectafer® can be marketed starting July 1, 2026, pending FDA approval.

How many patients in the U.S. have been treated with Injectafer®?

Over 1.7 million patients in the U.S. have been treated with Injectafer®.

Who are the parties involved in the settlement regarding Injectafer®?

The settlement involves Vifor Pharma, American Regent, Mylan Laboratories, and Sandoz.

What is the significance of the patent litigation settlement for GNHAY investors?

The settlement allows Vifor Pharma to refocus on addressing iron deficiency anemia, although it poses a risk of generic competition starting in 2026.